Drug Patent List
First Filer Exclusivity TimelineNew
Newsletter
Weekly Digest

Pharsight

Beigene Drug Patent Portfolio

Beigene's Family Patents


Family Patents





Clinical Trials

Recent Clinical Trials by Beigene:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab BeiGene NA COMPLETED
(Aug 1, 2026)
PHASE1, PHASE2
Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer BeiGene NA COMPLETED
(Aug 1, 2026)
PHASE1
Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants BeiGene NA COMPLETED
(Aug 1, 2026)
PHASE1
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer BeiGene NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors BeiGene NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma BeiGene NA COMPLETED
(May 1, 2026)
PHASE2
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma BeiGene NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma BeiGene NA COMPLETED
(Mar 1, 2026)
PHASE3
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) BeiGene NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib BeiGene NA COMPLETED
(Mar 1, 2026)
PHASE2


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Beigene News

Market Unfazed by Drugmaker's Recovery Efforts - Benzinga

15 May, 2025

BeiGene marks a significant profit achievement driven by rising pharmaceutical sales - Insights for global investors in Chinese stocks.

15 May, 2025

Summit Therapeutics Reports Smaller-Than-Expected Loss in Q1, No Sales Recorded - TradingView

02 May, 2025

Reasons Behind Summit Therapeutics' Significant Surge Today - The Globe and Mail

23 Apr, 2025

See More